Liquidia Corporation (LQDA) received a notice that officer Jason Adair intends to sell common stock under Rule 144. The notice covers up to 73,631 shares of common stock, based on a holding of 73,631 shares with an aggregate market value of $5,231,482.55 as of August 21, 2026, when 89,508,891 shares were outstanding. The planned sales relate to shares acquired through the exercise of stock options for 31,799 shares and the vesting of restricted stock units for 41,832 shares, all originally issued by Liquidia. A prior sale of 7,863 shares for $562,288.70 during the past three months is also disclosed.
Liquidia Corp (LQDA) director Katherine Rielly-Gauvin reported a two-day option exercise and share sale sequence under a Rule 10b5-1 trading plan. On August 19–20, 2026, she exercised non-qualified stock options for a total of 55,182 shares of common stock at exercise prices of $2.51 and $2.59 per share, and sold 55,182 shares of common stock in open-market transactions. The reported sales were at volume-weighted average prices of $74.9941 (range $73.28–$76.37) and $72.2273 (range $71.00–$74.35). Her reported holdings include 5,882 restricted stock units granted on June 16, 2026, none of which had vested as of this filing.
Liquidia Corp (LQDA) reported that its Chief Medical Officer, Rajeev Saggar, exercised a non-qualified stock option for 50,000 shares of common stock at an exercise price of $3.73 per share. On the same date, he sold 50,000 shares of common stock at a volume weighted average price of $74.06, and two days earlier sold an additional 29,534 shares at a volume weighted average price of $76.84. Following the option exercise, he continued to hold 150,000 stock options; separate footnote disclosure indicates additional holdings of unvested RSUs and shares acquired under the employee stock purchase plan.
Liquidia Corp (LQDA) received a notice that director Katherine T. Rielly-Gauvin plans to sell up to 55,182 shares of Liquidia common stock. The shares are to be obtained through the exercise of stock options with cash payment and sold through Morgan Stanley Smith Barney LLC.
The filing lists an aggregate market value of approximately $4,101,678.06 for the shares to be sold and indicates 89,508,891 Liquidia common shares outstanding as of 08/19/2026. The remarks state that the securities were and will be received upon option exercises over the next three months, with acquisition and payment occurring on the exercise/sale dates.
Liquidia Corp (LQDA) received a notice under Rule 144 for a planned resale of common stock by officer Rajeev Saggar. The notice covers 50,000 shares of common stock, to be acquired through a stock option exercise for cash on 08/19/2026 and sellable through Morgan Stanley Smith Barney on NASDAQ. Over the prior three months, Saggar reported Rule 144 sales of 29,534 shares on 08/17/2026 and 9,926 shares on 07/13/2026.
Liquidia Corporation (LQDA) reports a planned sale of up to 29,534 shares of common stock through Morgan Stanley Smith Barney LLC, with an indicated aggregate market value of $2,269,380.75. Shares outstanding were 89,508,891; this is a baseline figure, not the amount being sold. The sale is expected around 08/17/2026 on NASDAQ. The shares relate to vested equity awards, including Performance Shares and Restricted Stock. In the past three months, an affiliate, Rajeev Saggar, sold 9,926 common shares for $709,782.87.
Liquidia Corp investor Paul B. Manning and affiliated entities report updated beneficial ownership of the company’s common stock in Amendment No. 5. Mr. Manning has sole voting and dispositive power over 4,946,771 shares and shared voting and dispositive power over 914,724 shares, representing 6.5% of the common stock. PD Joint Holdings, LLC, Series 2016-A holds 198,413 shares (0.2%), and BKB Growth Investments, LLC holds 716,311 shares (0.8%). Percentages are based on 89,508,891 shares outstanding as of July 29, 2026.
Liquidia Corporation reported a sharp turnaround for the three and six months ended June 30, 2026, driven by commercialization of YUTREPIA and profit-sharing on treprostinil injection. Total revenue was $171.7 million for the quarter and $304.5 million for the first half of 2026, up from $8.8 million and $12.0 million in the prior-year periods. Net income was $74.7 million for the quarter and $127.6 million year-to-date, compared with net losses of $41.6 million and $79.9 million a year earlier.
Cash and cash equivalents were $284.2 million and total assets $521.9 million as of June 30, 2026, against total liabilities of $326.8 million, including $176.1 million of long-term debt under a revenue interest financing agreement that carries fixed payments and a minimum cash covenant of $15.0 million. Inventory and property, plant and equipment increased as the company scaled manufacturing. Management notes an accumulated deficit of $498.7 million but believes existing cash will cover obligations and covenants for at least the next twelve months while continuing YUTREPIA commercialization and L606 development, subject to execution and legal and regulatory risks.
Liquidia Corporation reported a strong turnaround for the quarter ended June 30, 2026, driven by the commercial launch of YUTREPIA. Total revenue was $171.7 million, up sharply from $8.8 million a year earlier, primarily from YUTREPIA product sales.
The company generated net income of $74.7 million and non-GAAP Adjusted EBITDA of $96.3 million, marking a fourth consecutive quarter of increasing profitability. Cash and cash equivalents rose to $284.2 million as of June 30, 2026, compared with $190.7 million at December 31, 2025, while total stockholders’ equity increased to $195.1 million.
Research and development expenses grew to $17.2 million, reflecting higher investment in the L606 program and YUTREPIA-related activities, and selling, general and administrative expenses increased to $57.4 million to support commercialization. The company notes that maintaining YUTREPIA’s approval and ongoing commercialization remains subject to patent litigation in which an opposing party is seeking injunctive relief that could halt sales.
Liquidia Corporation’s common stock is held by a group of investment funds managed by Farallon Capital Management, L.L.C., which together report beneficial ownership of 8,365,038 Shares of Liquidia common stock. This position represents 9.4% of the outstanding class as reflected in the Schedule 13G/A (Amendment No. 3).
The reporting structure is that the Shares are held directly by a set of investment partnerships collectively referred to as the Farallon Funds, while Farallon Capital Management, L.L.C. and fifteen individual managing or senior managing members are reporting persons. For these Shares, the reporting persons disclose shared voting power and shared dispositive power over 8,365,038 Shares and no sole voting or dispositive power. The Farallon Funds have the right to receive dividends and proceeds from any sale of these securities.